Lv1
40 积分 2025-06-18 加入
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
1个月前
已完结
Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment
1个月前
已完结
Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes
1个月前
已完结
Bone resorption is unchanged by liraglutide in type 2 diabetes patients: A randomised controlled trial
1个月前
已完结
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study
2个月前
已完结
Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults
2个月前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
2个月前
已完结
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
2个月前
已完结
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
2个月前
已完结
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
2个月前
已完结
皖公网安备34019202002308
